| This week's sponsor is Bracket. | | | |
Featured Story | | | Monday, June 12, 2017 There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it. |
|
|
| This week's sponsor is Precision For Value. | | | 10 case studies about changing payer behavior
Precision for Value, the recognized authority on payers, regulators & market access needs, has made their best case studies available for the first time. Get insights on biosimilar strategies, FDAMA 114, pricing considerations and more.
Download now |
Top Stories Monday, June 12, 2017 Competing with Sanofi blockbuster Lantus is no easy task, but that's exactly what Novo Nordisk's long-acting insulin Tresiba has to do. Thanks to new data, though, the drugmaker can safely say its newcomer poses no increased heart risks—and it has some advantages over its rival, too. Saturday, June 10, 2017 Boehringer Ingelheim and Eli Lilly still don’t know what’s responsible for the dramatic reduction in cardiovascular death risk that their diabetes med Jardiance (empagliflozin) posted in its outcomes trial. But they know what isn’t. Saturday, June 10, 2017 At last year’s American Diabetes Association annual meeting, Merck & Co. and Pfizer rolled out positive results from two phase 3 studies they hoped would buoy SGLT2 candidate ertugliflozin once it got to market. And this year, they’re doing it again. Sunday, June 11, 2017 Sanofi and Regeneron still have months to wait for final data from a key cardiovascular outcomes study of their PCSK9 therapy Praluent. But the pair now has results in hand suggesting the med can safely cut "bad" cholesterol in Type 2 diabetes patients at high risk of CV problems. Sunday, June 11, 2017 Novo Nordisk is in a tough market race against Sanofi with combo product Xultophy, which hit the market after the French drugmaker’s Soliqua. New basal-bolus-topping data could give the med a leg up. Monday, June 12, 2017 Eli Lilly and Boehringer Ingelheim have reason to believe their SGLT2 inhibitor, Jardiance, may be able to improve outcomes for chronic kidney disease patients—so they’re putting the med to the test. Saturday, June 10, 2017 Sanofi’s Toujeo has plenty of competition in the basal insulin market, but new real-world data shows it may outdo its peers at cutting the risk of hypoglycemia for older patients. And Sanofi's planning three real-world follow-ups, a "major shift" from its usual data approach. Friday, June 9, 2017 Lexicon Pharmaceuticals has posted upbeat data from another phase 3 trial of its Sanofi-partnered dual SGLT1 and SGLT2 inhibitor sotagliflozin. More patients in the treatment arm hit an established target for glycemic control than did in the control cohort, resulting in Lexicon chalking up its third phase 3 success for the diabetes tablet. Thursday, June 8, 2017 Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward. | This week's sponsor is Cmed. | | | |
Resources Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored by Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Systems Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored by: Halo Pharmaceuticals Agile. Flexible. Collaborative. Proven. That’s Halo Pharma – making contract clinical development and commercial manufacturing go smoothly. Presented by: Covance Discover how you can successfully mitigate risks and maximize trial success by creating a comprehensive strategy that plans for the difference in immunotherapy development and proactively monitors execution. Sponsored by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored by: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Powering Innovation in Pharma Production September 25-27, 2017 | Las Vegas, NV FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA |
